NCT06533553进行中（未招募）2 期
An Open-label Phase II Study to Assess the Pharmacodynamic (PD) Effects of Dexpramipexole in Participants With Eosinophilic Chronic Obstructive Pulmonary Disease (COPD)
Areteia Therapeutics23 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2024年7月9日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
- 试验地点
- 23
- 主要终点
- Geometric mean change in the blood AEC from baseline to Week 16
研究概览
简要总结
This is an open-label Phase II study assessing the PD of dexpramipexole 150 mg twice daily (BID) in participants with eosinophilic COPD. This study will help characterize the profile and duration of reductions of blood absolute eosinophil counts (AEC).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent form prior to any study-specific procedures.
- •Male or female ≥40 to ≤80 years of age at Screening Visit.
- •Physician diagnosis of COPD for at least 2 years prior to the Screening Visit in accordance with the definition by the American Thoracic Society/European Respiratory Society
- •Current or former smokers with a cigarette smoking history of ≥10 pack years at the Screening Visit calculated as (number of pack years = [number of cigarettes per day/20] multiplied by number of years smoked). Former smokers are defined as those who meet the pack-year history but have stopped smoking for at least 6 months prior to the Screening Visit.
- •Spirometry: post-BD FEV1/FVC <0.70 and post-BD FEV1 >20% and ≤60% of predicted normal values at the Screening Visit.
- •Documented history of exacerbation risk defined as exacerbation history of ≥1 moderate* or ≥1 severe** within 2 years prior to the Screening Visit.
- •Background ICS-based therapy (ICS+ long-acting β2 agonist [LABA], or ICS + long-acting muscarinic antagonist [LAMA], or ICS + LAMA + LABA) for ≥12 weeks prior to enrollment with a stable dose of medication for ≥4 weeks prior to the Screening Visit.
- •Evidence of an eosinophilic phenotype: Participants with blood eosinophils ≥0.30x109/L at the Screening Visit.
- •Negative urine pregnancy test for women of childbearing potential (WOCBP) at the Screening and Baseline Visits.
- •WOCBP (after menarche) must use e methods of birth control from the Screening Visit through the End of Study Visit..
排除标准
- •A current diagnosis of asthma or any history of asthma diagnosis when ≥40 years of age.
- •Significant pulmonary disease other than COPD (eg, α-1 antitrypsin deficiency, active tuberculosis, lung fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, lung cancer, clinically significant bronchiectasis, Churg-Strauss Syndrome) or another diagnosed pulmonary or systemic disease associated with elevated eosinophil counts.
- •Pneumonia, upper or lower respiratory tract infection or acute exacerbation of COPD within 4 weeks prior to or during the Screening Phase.
- •Treatment with a biologic investigational drug in the last 5 months prior to the Screening Visit. Treatment with non-biologic investigational drugs in the previous 30 days or five-half-lives prior to the Screening Visit, whichever is longer. Treatment with GSK3511294 (long-acting anti-interleukin-5) in the past 12 months.
- •Treatment with any of the following monoclonal antibody therapies within 120 days prior to the Baseline Visit: benralizumab, dupilumab, mepolizumab, reslizumab, omalizumab, tezepelumab, or tralokinumab.
- •Treatment with pramipexole (Mirapex®) within 30 days of the Baseline Visit.
- •Treatment with selected drugs known to have a substantial risk of neutropenia in the past 30 days prior to the Screening Visit.
- •Treatment with selected drugs known to have a substantial risk of QT prolongation in the past 30 days prior to the Screening Visit.
- •Participants who are participating in the acute phase of a pulmonary rehabilitation program, ie, who started rehabilitation.
- •History of malignancy that required surgery (excluding local and wide-local excision), radiation therapy and/or systemic therapy during the 2 years prior to the Baseline Visit.
- •History of human immunodeficiency virus infection or chronic infection with hepatitis B or C.
- •Neutrophil count <2.000x109/L at the Screening Visit.
- •Renal dysfunction, defined as an estimated glomerular filtration rate <60 mL/min/1.73m2 at the Screening Visit (using the Chronic Kidney Disease Epidemiology Collaboration) formula.
- •Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), >3x the upper limit of normal (ULN), or total bilirubin >2x ULN at the Screening Visit confirmed by a repeat abnormal measurement of the relevant value(s), at least 1 week apart.
- •History of New York Heart Association class IV heart failure or last known left ventricular ejection fraction <25%.
- •Corrected QT interval by Fridericia (QTcF) interval >450 ms for males and >470 ms for females at the Screening Visit or QTcF ≥480 ms for participants with bundle branch block.
- •Pregnant women or women breastfeeding.
- •Males who are unwilling to use an acceptable method of birth control during the entire study period (ie, condom with spermicide).
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
研究组 & 干预措施
150 mg dexpramipexole BID
Experimental
150 mg dexpramipexole oral tablet taken twice a day
干预措施: Dexpramipexole Dihydrochloride (Drug)
结局指标
主要结局
Geometric mean change in the blood AEC from baseline to Week 16
时间窗: Baseline, Week 16
次要结局
- Pre-BD FEV1(Baseline, Week 16)
- Post-BD FEV1(Baseline, Week 16)
- St George's Respiratory Questionnaire for COPD Patients (SGRQ-C)(Baseline, Week 16)
- COPD Assessment Test (CAT)(Baseline, Week 16)
研究者
研究点 (23)
Loading locations...
相似试验
已完成
3 期
Phase 3 Study of Dexpramipexole in ALSAmyotrophic Lateral SclerosisNCT01281189Knopp Biosciences942
终止
2 期
Phase II Study of PX-12 in Patients With Advanced Pancreatic CancerPancreatic NeoplasmsNCT00417287Cascadian Therapeutics Inc.17
终止
3 期
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.Eosinophilic AsthmaAsthmaEosinophilic AsthmaNCT05763121Areteia Therapeutics1,061
进行中（未招募）
3 期
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic AsthmaEosinophilic AsthmaEosinophilic AsthmaAsthma AttackNCT05748600Areteia Therapeutics600
已完成
2 期
Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and EosinophiliaChronic Sinusitis With Nasal Polyps and EosinophiliaNCT02217332Knopp Biosciences20